Doctors and patient groups said it was a "quantum leap" for people with melanoma, one of the most dangerous and aggressive forms of cancer. The Therapeutic Goods Administration has approved the intravenous treatment after clinical trials showed ipilimumab can almost double the number of patients alive three years after diagnosis. "The people who are told to go home and get their affairs in order, they are the people that will benefit from this drug," Melanoma Patients Australia CEO Lisa McFadyen said.
